PMID- 36324107
OWN - NLM
STAT- MEDLINE
DCOM- 20221223
LR  - 20221223
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Nov 2
TI  - The predictive value of fibrinogen in the occurrence of mild cognitive impairment 
      events in patients with diabetic peripheral neuropathy.
PG  - 267
LID - 10.1186/s12902-022-01185-2 [doi]
LID - 267
AB  - BACKGROUND: Research suggests that fibrinogen (Fib) is related to mild cognitive 
      impairment (MCI) and diabetic peripheral neuropathy (DPN) and the risk of MCI in 
      patients with DPN is greatly increased, although no studies have evaluated the 
      predictive value of Fib for the risk of MCI in patients with DPN. METHODS: This 
      prospective observational clinical study enrolled 207 type 2 diabetes mellitus 
      (T2DM) patients, who were divided into diabetes with no neuropathy (102 cases) 
      and diabetes with neuropathy (105 cases) groups. Meanwhile, 90 healthy unrelated 
      subjects were recruited as controls. The incidence of MCI in the DPN patients was 
      followed up for 2 years. Divide patients in the DPN group into subgroups 
      according to whether MCI occur, use multivariate logistic regression to analyze 
      independent factors of MCIs in DPN patients within 2 years, and use ROC curve to 
      analyze the predictive value of Fib for MCI in DPN patients. RESULTS: Fib levels 
      were significantly higher in diabetic subjects with neuropathy compared with 
      those without (P < 0.001). In further subgroup analysis of DPN patients who were 
      divided according to the occurrence of MCI, baseline data of the MCI subgroup 
      showed Fib levels were higher than that in the non-MCI group while education 
      levels declined (P < 0.001). The education level and increased Fib levels were 
      independent factors for the occurrence of MCI within 2 years after the onset of 
      DPN (OR = 0.769, 95% CI: 0.605 ~ 0.968, P = 0.037; OR = 2.674, 95% CI: 
      1.094 ~ 3.168, P = 0.002). The ROC curve indicated that the predictive value of 
      Fib was (AUC = 0.764, 95% CI: 0.671 ~ 0.842, P < 0.001). CONCLUSIONS: Fib may 
      function as a predictor for assessing the risk of MCI in DPN patients.
CI  - (c) 2022. The Author(s).
FAU - Zhuang, Yong
AU  - Zhuang Y
AD  - Department of Endocrinology, The Second Affiliated Hospital of Fujian Medical 
      University, No.950 Donghai Street, Fengze District, Quanzhou City, Fujian 
      Province, China.
FAU - Huang, Huibin
AU  - Huang H
AD  - Department of Endocrinology, The Second Affiliated Hospital of Fujian Medical 
      University, No.950 Donghai Street, Fengze District, Quanzhou City, Fujian 
      Province, China.
FAU - Fu, Zhenfei
AU  - Fu Z
AD  - Department of Endocrinology, The Second Affiliated Hospital of Fujian Medical 
      University, No.950 Donghai Street, Fengze District, Quanzhou City, Fujian 
      Province, China.
FAU - Zhang, Jinying
AU  - Zhang J
AD  - Department of Neurology, The Second Affiliated Hospital of Fujian Medical 
      University, Quanzhou, 362000, China.
FAU - Cai, Qingyan
AU  - Cai Q
AD  - Department of Endocrinology, The Second Affiliated Hospital of Fujian Medical 
      University, No.950 Donghai Street, Fengze District, Quanzhou City, Fujian 
      Province, China. 551695787@qq.com.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20221102
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
RN  - 9001-32-5 (Fibrinogen)
SB  - IM
MH  - Humans
MH  - *Cognitive Dysfunction/diagnosis/epidemiology/etiology
MH  - *Diabetes Mellitus, Type 2/complications
MH  - *Diabetic Neuropathies/diagnosis/epidemiology/etiology
MH  - Fibrinogen
MH  - Risk Factors
PMC - PMC9628023
OTO - NOTNLM
OT  - Diabetic peripheral neuropathy
OT  - Fibrinogen
OT  - Mild cognitive impairment events
OT  - Predictive value
COIS- The authors have no relevant financial or non-financial interests to disclose.
EDAT- 2022/11/04 06:00
MHDA- 2022/11/05 06:00
PMCR- 2022/11/02
CRDT- 2022/11/03 00:47
PHST- 2022/04/29 00:00 [received]
PHST- 2022/10/24 00:00 [accepted]
PHST- 2022/11/03 00:47 [entrez]
PHST- 2022/11/04 06:00 [pubmed]
PHST- 2022/11/05 06:00 [medline]
PHST- 2022/11/02 00:00 [pmc-release]
AID - 10.1186/s12902-022-01185-2 [pii]
AID - 1185 [pii]
AID - 10.1186/s12902-022-01185-2 [doi]
PST - epublish
SO  - BMC Endocr Disord. 2022 Nov 2;22(1):267. doi: 10.1186/s12902-022-01185-2.